Daily Stock List
Triton Emission Solutions, Inc. (DSOX)
Wall Street Resources and Gold Investment Letter reported on Triton Emission Solutions, Inc. (DSOX), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.
OTCQB-listed Triton Emission Solutions, Inc. develops and markets environmental and pollution emission control solutions to a worldwide market. The Company’s engineers work to build proprietary products that reduce harmful chemical emissions into the ocean and atmosphere. Triton’s proprietary DSOX-15 and DSOX-20 Fuel Purification Systems are cost-effective technologies designed to remove sulfur from fuel.
The Company was formerly known as Poly Shield Technologies, Inc. It changed its name to Triton Emission Solutions, Inc. in August 2014.
The Company's proprietary DSOX-15 and DSOX-20 Fuel Purification Systems, and its exhaust gas scrubber technology, NJORD, are cost-effective technologies. The design of these are to reduce harmful chemical emissions into the ocean and atmosphere in an effort to meet the increased emissions regulations that came into effect on January 1, 2015.
Currently, the DSOX-15 and DSOX-20 Fuel Purification Systems are targeted at the maritime industry. This includes vessels for cruise-line, freight shipping and tanker companies. These technologies can be installed during normal vessel operation without the need to use expensive dry dock time. These technologies have global applications, which are not limited to the maritime industry.
Triton Emission Solutions has contracted with numerous shipping companies for installation of its DSOX-15 System, with options for a total of 62 installations. All of these will be upgraded to the new DSOX-20 System. The Company’s DSOX-20 fuel scrubber is a pre-combustion desulfurization system. It uses Triton’s proprietary and proven technology as its basis.
Through integrating this proven platform with additional new proprietary technologies that react and release the sulfur in the fuel, the Company’s DSOX-20 system can scrub and wash the sulfur from the fuel. As a by-product, the system additionally removes other harmful alkali metals including vanadium, sodium and calcium.
This past December, Triton Emission Solutions announced the establishment of its wholly-owned subsidiary in Sweden, Triton Emission Solutions International AB. The Subsidiary will direct its efforts on sales and further Research & Development of the DSOX-20 Fuel Purification System and the Company's newly developed NJORD Exhaust Gas Scrubber System.
Triton Emission Solutions, Inc. (DSOX), closed Tuesday's trading session at $0.1705, down 6.06%, on 20,179 volume with 8 trades. The average volume for the last 60 days is 44,771 and the stock's 52-week low/high is $0.15/$1.08.
New Western Energy Corp. (NWTR)
PennyStocks24, Trading Wall St, DSR News, BabyBulls, and Penny Stock Pinnacle reported on New Western Energy Corp. (NWTR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Founded in 2008, New Western Energy Corp. is an independent energy company that lists on the OTC Markets’ OTCQB. The Company engages in the acquisition, exploration, development, and production of oil, gas, and other minerals in North America. It is centering on acquiring land leases for properties in the United States that have shown favorable characteristics for the discovery of oil, natural gas, and other minerals. The Company is also focusing on entering into joint ventures to acquire assets in areas in the continental U.S. New Western Energy is headquartered in Irvine, California.
The Company acquired 100 percent of Royal Texan Energy Co. (now its wholly-owned subsidiary) in January 2012. New Western Energy has strategic partnerships with Petroleum Energy Management Co. (PEMCO) and Carroll Energy, LLC. Established in 2004, PEMCO established to work within the mid-continent marginal well market. Carroll Energy of Independence, Kansas, is a family-owned company with over 30 years of experience in the oil and gas industry.
New Western Energy’s current leaseholds are in Oklahoma, Kansas, Texas, and Pennsylvania. In September 2014, it announced that it signed a Letter of Intent (LOI) to acquire all of the Osage County, Oklahoma oil and gas assets from a long-time private independent producer in the area. The assets comprise 10 contiguous quarter sections totaling 1,600 acres. Osage County is located in the Central Oklahoma platform.
Furthermore, in September 2014, New Western Energy announced that it signed an LOI to acquire majority control of Island Energy Partners, LLC (IEP). IEP owns oil and gas wells, leases, and completion tools and equipment. The properties, wells, and completion equipment are in the Rio Vista Gas Field in California. There are 15 producing wells of interest on leases consisting of 1,300 acres.
Recently, New Western Energy announced it signed and closed a definitive agreement on the majority control in a newly formed subsidiary jointly owned with Forward Energy LLC of Montana and named NWE Forward Energy LLC. The New Western Energy subsidiary will include all rights, title and interest in and to Forward Energy's current and future oil and gas wells, leases, and designated completion equipment license and perpetuity rights.
Last week, New Western Energy announced that it signed a Securities Purchase Agreement with Fodere Titanium Limited, a UK-based company (FODERE) that holds the exclusive worldwide rights to extraction technologies designed in union with a prominent English university that allow for the zero waste recovery of high-grade titanium dioxide (TiO2), high-purity vanadium (V), high carbon steel and other high-value elements from either tailings stockpiles or direct mineral deposits. The FODERE process was developed by the School of Chemical and Process Engineering at a world renowned English engineering university. It allows extraction with significant yield of low-grade titanium from tailings and ores.
New Western Energy Corp. (NWTR), closed Tuesday's trading session at $0.167, up 15.09%, on 1,368,607 volume with 252 trades. The average volume for the last 60 days is 55,185 and the stock's 52-week low/high is $0.035/$0.90.
FluoroPharma Medical, Inc. (FPMI)
TaglichBrothers reported earlier on FluoroPharma Medical, Inc. (FPMI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Montclair, New Jersey-headquartered FluoroPharma Medical, Inc. specializes in the development of novel diagnostic imaging products, which utilize Positron Emission Tomography (PET) technology for the detection and assessment of disease before clinical manifestation. The Company is a biopharmaceutical entity engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. FluoroPharma Medical has licensed technology from the Massachusetts General Hospital in Boston, Massachusetts. The Company lists on the OTCQB.
Patents related to FluoroPharma Medical’s portfolio of imaging compounds have been issued in the U.S., Europe, China, Japan, Canada, Australia, and Mexico. The Company’s initial emphasis is the development of innovative PET imaging agents. It is advancing two products in clinical trials for assessment of acute and chronic forms of coronary artery disease.
The design of these first in class agents is to target, quickly, myocardial cells. Other products in development include agents for the detection of inflamed atherosclerotic plaque in peripheral arteries, agents with the potential to image Alzheimer's disease, and agents that could potentially be used for imaging specific cancers.
CardioPET™ is one of FluoroPharma's first in class PET imaging products. CardioPET™ is a perfusion and fatty acid uptake indicator. The design of it is for use as a cardiac imaging agent. It may be a more specific alternative to presently available diagnostic tests.
FluoroPharma Management believes its pharmacokinetic characteristics could be especially valuable in patients who are unable to exercise. FluoroPharma Medical announced in December 2014 scheduled completion of enrollment in a Phase II Clinical Trial of CardioPET™ (18F FCPHA) for Assessment of Coronary Artery Disease (CAD).
FluoroPharma also has its BFPET PET Scan Imaging Agent. BFPET is a Flourine-18 labeled tracer. The design of it is to enter the myocardial cells in direct proportion to blood flow and cell membrane potential.
FluoroPharma Medical, Inc. (FPMI), closed Tuesday's trading session at $0.4699, down 3.61%, on 9,300 volume with 4 trades. The average volume for the last 60 days is 48,653 and the stock's 52-week low/high is $0.3272/$0.92.
Falconridge Oil Technologies Corp. (FROT)
The Bull Report, Wall Street Wolves, PremiereStockAlerts, MyBestStockAlerts, Smart Penny Stocks, Wall Street Elite, and ProfitableTrading reported earlier on Falconridge Oil Technologies Corp. (FROT), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Falconridge Oil Technologies Corp. is an emerging oil and gas technology company based in Richmond Hill, Ontario. The Company focuses on licensing, developing, and deploying inventive technologies to enable operators to economically increase production levels, expand known oil and gas reserves, and reduce environmental impact. Falconridge Oil Technologies’ shares trade on the OTC Markets Group’s OTCQB.
The Company provides operators a lower-cost alternative to drilling a new well. Its aim is to shift the industry and social paradigm away from new drilling and towards increasing efficiency of current extraction in existing well-bores to increase recovery of oil and gas. Its licensed and patented third-generation Terra Slicing Technology™ (TST™) is an option as an alternative to traditional fracturing/fracking on existing low producing wells throughout Canada and the United States.
Terra Slicing is an advanced proprietary excavation and hydro cutting technology. TST is applied to producing well assets, dead wells, non-performing well assets, as well as low yield assets. Terra Slicing Technology™ (TST™) uses patented oil and gas completion technology to increase the production of under-performing oil and gas assets by way of precision excavation and cutting of damaged productive hydrocarbon zones. This increases permeability, creates previously non-existent vertical permeability, increases the overall drainage area of the well, and avoids further damage caused by explosive charge perforation.
TST is used to enhance "dead" or non-performing well assets. This fundamentally revitalizes the per-existing well and establishes a flow rate with a significant percentage of its initial production. An operator, through applying TST, will retrieve a substantial portion of the well reserves still locked in the ground. TST is applicable on land or marine environments. It may be used for oil and gas well applications, in vertical or horizontal formats.
In late January, Falconridge Oil Technologies announced the signing of a Letter of Intent (LOI) with Tubestar Oil and Gas Services Pvt. Ltd. of India. This is for representation and deployment of its Terra Slicing well enhancement and oil recovery technology (TST). Tubestar will target major oil and gas assets within its service range for targeted deployment of TST. Falconridge will work closely with Tubestar for assessment of properties in the India market for potential deployment of TST. Falconridge will grant rights to Tubestar for marketing, representation, and deployment of TST to its clients.
Furthermore, the Company has its Terra-Seal™. This is a patented abrasive jet cutting completion process to cut smoothly through casing with high-pressure slurry (up to four or more casings). The design of Terra-Seal™ is to excavate vertical windows in the cement and deep into near well-bore rock in two 180o-phased directions (up to 4 sets).
Falconridge Oil Technologies Corp. (FROT), closed Tuesday's trading session at $0.16, even for the day, on 25,949 volume with 13 trades. The average volume for the last 60 days is 112,656 and the stock's 52-week low/high is $0.12/$1.32.
Medican Enterprises, Inc. (MDCN)
PennyStocks24, Pennybuster, Fortune Stock Alerts, Penny Stock Circle, 1-2-3 Stock Alerts, and StockMarketQuote.us reported on Medican Enterprises, Inc. (MDCN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Medican Enterprises, Inc. is a bio-pharmaceutical company that concentrates on going after business opportunities in the emerging medical and recreational marijuana sector. Via its subsidiaries, Medican is looking to invest in its businesses associated with the growing, marketing, research and development (R&D), training, distribution and retail sale of medical and recreational marijuana in the United States and Canada. Medican Systems is the wholly-owned operating subsidiary of Medican Enterprises. Medican Enterprises has its corporate office in Las Vegas, Nevada.
Medican’s focus is on cultivating strains of Cannabis with standardized potencies and verified purity: High THC / Low CBD; Medium THC / Low CBD; Medium THC / Medium CBD; and Low TCH / High CBD. Concerning Financial Consulting, Medican provides strategic planning, valuation, project debt, and corporate finance solutions to its joint venture (JV) Partners. This is to capitalize on the growing MMJ market and fund multiple facilities.
The Company’s Medican Systems is the operating arm of Medican Enterprises’ Medical Marijuana Cultivation and Research Facilities. Medican Systems is working to become one of Canada’s first commercially Licensed Producers of Medical Marijuana (MMJ) under the new program Marijuana for Medical Purposes Regulation (MMPR).
Medican has formed Medican (US) Systems, Inc., a wholly-owned subsidiary established to pursue business activities in the U.S. medical marijuana and recreational marijuana sectors. The new subsidiary looks for investments in commercial real estate, which it can lease to marijuana growers in states where growing is legal; and provide dispensary management and professional consulting services to the medical marijuana and recreational marijuana sectors. In addition, it will offer a wide assortment of leasing and financing solutions to dispensaries, kitchens, and cultivations centers.
In October 2014, Medican Enterprises’ announced that its wholly-owned subsidiary, Medican Systems, entered into a binding Letter of Intent (LOI) to acquire Future Harvest Development Ltd. Under the terms of the LOI, Medican Systems will acquire a 70 percent interest in Future Harvest, with an option to acquire the remaining 30 percent. Future Harvest Development is a foremost Canadian manufacturing company in the home and garden, indoor growing, and hydroponic sectors.
Last month, Medican Enterprises announced the formation of a new wholly-owned subsidiary, Medican Nations, LLC, as well as the appointment of Demitri Downing as CEO of Medican Nations. Medican Nations will focus on building strategic partnerships with Indian communities in the U.S. and Canada to create and build business solutions within the indoor gardening and marijuana industries.
Furthermore, last week, Medican Enterprises announced that the 67,000 square foot facility it is acquiring, located in Phoenix, Arizona, has received zoning approval and is now zone compliant for the operation of legal medical marijuana businesses.
Medican Enterprises, Inc. (MDCN), closed Tuesday's trading session at $0.0031, down 26.19%, on 12,778,417 volume with 106 trades. The average volume for the last 60 days is 2,767,506 and the stock's 52-week low/high is $0.004/$4.36.
Cocrystal Pharma, Inc. (COCP)
PennyStocks Forever reported on Cocrystal Pharma, Inc. (COCP), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
Bothell, Washington-headquartered Cocrystal Pharma, Inc. is a biotechnology company developing new antiviral therapeutics for human diseases. The Company merged in 2014 with Biozone Pharmaceuticals, Inc. It has earlier received strategic investments from Teva Pharmaceuticals, OPKO Health (OPK), and The Frost Group. OPKO Health and The Frost Group together own approximately 48 percent of Cocrystal Pharma. Cocrystal Pharma has five therapeutic programs targeting the Hepatitis C Virus (HCV), Influenza Virus, the Human Rhinovirus (HRV), Dengue Virus, and the Norovirus.
The Company focuses on the discovery and development of novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. It employs unique technologies and Nobel Prize winning expertise to create first- and best-in-class antivirals. The design of these technologies and its market-focused approach to drug discovery are to efficiently deliver small molecule therapeutics that are safe, effective, and convenient to administer.
Cocrystal Pharma is targeting two Hepatitis C replication enzymes with its Polymerase program at lead optimization stage and its Helicase program at lead identification stage. Its Influenza, HRV, Dengue, and Norovirus programs are targeting unmet multi-billion dollar market opportunities with first-in-class antivirals. Cocrystal Pharma has developed what it believes to be the first high-throughput screening technology for inhibitors of a key essential Ebola virus gene product. It employed its core platform technology to develop the in vitro test.
The Company is developing drug candidates specifically designed to be effective against all strains of the influenza virus and to have a high barrier to resistance. Selection of a lead compound for clinical development is planned to take place early in 2015. Regulatory filings to begin clinical studies for influenza are planned for December of this year.
Cocrystal Pharma’s Hepatitis C program continued to make progress in Q2 2014. The Company has selected CDI-244 for development as a treatment for patients with Hepatitis C (HCV). Cocrystal plans regulatory filings to start clinical trials of CDI-244 in early 2015.
Company scientists have made first-rate progress discovering potent inhibitors of the influenza endonuclease, an enzyme that is essential for viral genome replication. Selection of a lead compound for clinical development is planned to take place by early this year. Regulatory filings to start clinical studies for influenza are planned for December 2015.
Cocrystal Pharma announced this past November the closing of its merger with RFS Pharma, LLC. RFS Pharma is a privately owned biotech company founded by renowned drug developer, Dr. Raymond Schinazi.
Today, Cocrystal Pharma announced that it will present at the Barclays 2015 Global Healthcare Conference on Thursday, March 12, 2015 at 8:00 AM ET at Loews Miami Beach Hotel in Miami, Florida. Dr. Raymond F. Schinazi, co-chairman of the Board of Directors of Cocrystal Pharma, will be presenting on behalf of the Company.
Cocrystal Pharma, Inc. (COCP), closed Tuesday's trading session at $0.835, up 9.87%, on 1,147,041 volume with 346 trades. The average volume for the last 60 days is 1,039,784 and the stock's 52-week low/high is $0.252/$1.17.
FullCircle Registry, Inc. (FLCR)
Today we are highlighting FullCircle Registry, Inc. (FLCR), here at the QualityStocks Daily Newsletter.
FullCircle Registry, Inc. is an acquisition company headquartered in Shelbyville, Kentucky. It provides exit plans to successful profitable businesses in expanding business sectors. The Company’s mission is to provide a home for those who have developed successful companies and have no exit capabilities. FullCircle Registry has opened up subsidiaries to be homes for the Company’s acquisitions. FullCircle Registry’s shares trade on the OTCQB.
The Company’s focus is to provide exit capabilities for small to medium sized private, profitable companies via acquisition, to improve its stockholder value, while leaving those companies independent where possible to continue to be managed by the team that founded them, and subsequently providing liquidity and greater returns for the founder(s).
Companies that FullCircle Registry owns include FullCircle Entertainment, Inc. and FullCircle Medical Supplies, Inc. Regarding FullCircle Entertainment, the Company purchased Georgetown 14 Cinemas in 2010. It operates in Indianapolis, Indiana. Pertaining to FullCircle Medical Supplies, the Company is in the process of acquiring several DME businesses to provide full state coverage for Louisiana.
FullCircle Registry announced in December 2014 that its S-1 Registration Statement filed with the Securities and Exchange Commission (SEC) became effective, securing a $1.5M financing commitment from Kodiak Capital Group, LLC. The funding will provide working capital for operations, to develop the DME infrastructure, acquire DME businesses, and to retire some of FullCircle Registry’s debt, as defined in the Registration Statement. Kodiak Capital Group is an institutional investor based in Newport Beach, California.
FullCircle Registry CEO, Mr. Norman L. Frohreich, said this past December, "I am very pleased to have this facility in place as it offers FullCircle access to additional funds that may be required for working capital and to begin the acquisition of Durable Medical Equipment businesses (DMEs) in Louisiana and South Carolina. FullCircle has been searching for funding to proceed with its acquisition business model for some time. Over the last year FullCircle has issued Letters of Intent to purchase several medical supply businesses, using stock, notes and cash. The negotiations involving these acquisitions are contingent on securing capital.”
Overall, regarding its business focus, FullCircle Registry expects to provide its stock, notes, and cash for mergers as it develops an environment for the business owner to continue to manage the business after FullCircle acquires their business.
FullCircle Registry, Inc. (FLCR), closed Tuesday's trading session at $0.0057, up 14.00%, on 556,583 volume with 6 trades. The average volume for the last 60 days is 532,558 and the stock's 52-week low/high is $0.0035/$0.06.
Consorteum Holdings, Inc. (CSRH)
The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.007, up 40.00%, on 8,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 109,625, and its 52-week low/high is $0.0016/$0.018.
Consorteum Holdings, Inc. (CSRH) has spent the last 3 years developing relationships and licensing agreements to take the center stage in the emerging market of mobile gaming. The company has the capability to deliver rich mobile content to end users who will use their smart phones in ways that could not even have been imagined five years ago.
Specializing in delivery of mobile content, mobile payment solutions and products through a mix of on-deck partnerships, license agreements, and joint venture revenue share arrangements, the company operates as a technology and services aggregator to meet the diverse needs of its client base. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.
ThreeFiftyNine Inc., a wholly owned subsidiary, hired a software development team that had previously designed the world’s first regulatory compliant mobile platform for delivery of gaming content created by a third party. The platform, which has met the rigorous standards of the Nevada Gaming Board, the gold standard in regulatory gaming, represents the first generation software delivery platform for mobile devices. The development team spent the past 5 years and millions of dollars in non-recurring engineering costs to complete the development of the platform. At the heart is the capability to deliver any digital content across any cellular network to any mobile device. This key differentiator makes it possible for Consorteum to approach many different markets that are in the business of providing mobile connectivity and mobile content.
Consorteum’s mobile initiatives will benefit multiple business verticals. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer
Consorteum Holdings, Inc. Company Blog
Consorteum Holdings, Inc. News:
Consorteum Holdings Signs License Agreement With NYG Holdings
Consorteum Holdings Signs Mobile Application Development Contract With Bet Butler Limited
Consorteum Holdings Launches New Mobile Results App for Popular Keno Game
One World Holdings, Inc. (OWOO)
The QualityStocks Daily Newsletter would like to spotlight One World Holdings, Inc. (OWOO). Today, One World Holdings, Inc. closed trading at $0.0039, up 21.88%, on 6,345,363 volume with 72 trades. The stock’s average daily volume over the past 60 days is 3,820,522, and its 52-week low/high is $0.0008/$0.2998.
One World Holdings, Inc. (OWOO) subsidiary, The One World Doll Project, was established in 2010 to make a significant positive cultural impact through the doll category, transcending global and ethnic borders to create positive self-image in young women and girl around the world. Led by worldwide famous doll designer Stacy McBride-Irby, The One World Doll Project team has more than 50 collective years in the doll and toy industry and is dedicated and armed with the experience to ensure that the dolls are of the highest quality and value.
In 2013, the company released its Prettie Girls!™ line of multi-cultural fashion dolls uniquely designed with individual physical attributes, personal stories and hobbies, and goals and inspirations. For young girls, the dolls are a friend, a partner in play, and a glimpse of their biggest, brightest dreams. For young women, the dolls are a symbol of who they are and what they can achieve. For doll connoisseurs, The One World Doll Project promises stylish works of art that will become a vital part of a growing collectors’ market.
The One World Doll Project also has a Signature Celebrity Collection of Prettie Girls! and in 2013 released its first celebrity collectors doll modeled after supermodel Cynthia Bailey from The Real Housewives of Atlanta. Since the release of the doll, it has been showcased with Synthia on The Arsenio Hall Show, What Happens Live with Andy Cohen and The Bethenny Show.
Using a web-based sales model, One World Holdings plans to quickly capture significant market share in the dolls and stuffed toys space. After securing a strong online presence, the company will focus on brick and mortar retailing as it moves toward the ultimate pursuit of expanding worldwide. The company has established distribution deals with Toys “R” Us, HEB, dollgenie.com, Tuckers Toy Shop, pattycakedoll.com, and has recently expanded its retail presence internationally with the People’s Pharmacy storechain in the Central American country of Belize. The Prettie Girls! Dolls have been featured in national and international media spotlights like CNN, The Wall Street Journal, Jet Magazine, Bloomberg.com, Parade.com, Dolls Magazine, The Toy Book, The Houston Chronicle and Houston Business Journal, and TheStreet.com. Disclaimer
One World Holdings, Inc. Company Blog
One World Holdings, Inc. News:
The One World Doll Project CEO Announces 2015 Revenue Projections in Stockholder Letter
The One World Doll Project and Doll Designer, Stacey Mcbride-Irby Featured in Huffington Post
The One World Doll Project Founder Interviews With CEOLIVE.TV; Updates on Toy Fair 2015
MIT Holding (MITD)
The QualityStocks Daily Newsletter would like to spotlight MIT Holding (MITD). Today, MIT Holding closed trading at $0.0748, up 6.86%, on 41,700 volume with 5 trades. The stock’s average daily volume over the past 60 days is 19,415, and its 52-week low/high is $0.032/$0.31.
MIT Holding (MITD), through its agents, facilitators and contractual obligations, offers professional outpatient medical care with ambulatory infusion therapies, home infusion services, and medical equipment delivery. The company is also pursuing government contacts to obtain approval to import pharmaceutical products into the Americas.
In support of these core services, MIT Holding provides expert legal, accounting, advisory and educational services to physicians, medical centers, hospitals, small and large businesses regarding the Affordable Care Act; offers travel and transportation services of medically challenged patients for medical needs and personal travel; and through its contracts is approved to, conduct and administer FDA clinical trials.
Collectively, these services contribute to MIT Holding’s strategy to provide custom prescription solutions in a variety of methods and generate multiple revenue streams. Following a successful reorganization initiative in January, 2014, MIT Holding is positioned to achieve 32% minimum net profits and has maintained profitability in its fiscal second and third quarters. This profitability validates the company’s business model and its approach to the evolving Affordable Health Care Act and its impact on the health services industry.
MIT Holding meets and/or exceeds major U.S. health insurance requirements and is therefore able to direct bill and receive payments from carriers on behalf of the patient its agents and its facilitators. This ability marks an important step in the company’s goal of developing the first-of-its-kind seamless transition for patient needs from hospital discharge to complete home recovery. This and other corporate initiatives are spearheaded by a management team committed to building shareholder value, revenues and corporate expansion while providing viable solutions to the perpetual changes in the health care sector. Disclaimer
MIT Holding Company Blog
MIT Holding News:
MIT Holding (MITD) Launches New Website with Investor Relations Suite
MIT Holding, Inc. Names Tommy J. Duncan as President
MIT Holding, Inc. (MITD) Announces Engagement of QualityStocks Investor Relations Services
Save The World Air, Inc. (ZERO)
The QualityStocks Daily Newsletter would like to spotlight Save The World Air, Inc. (ZERO). Today, Save The World Air, Inc. closed trading at $0.47, up 2.87%, on 350,416 volume with 60 trades. The stock’s average daily volume over the past 60 days is 123,453, and its 52-week low/high is $0.3401/$1.00.
Save The World Air, Inc. (ZERO) (“STWA”) provides the global energy industry with patent-protected industrial equipment designed to deliver measurable performance improvements to crude oil pipelines. Developed in partnership with leading crude oil production and transportation entities, STWA’s high-value solutions address the enormous capacity inadequacies of domestic and overseas pipeline infrastructures that were designed and constructed prior to the current worldwide surge in oil production.
In support of our clients’ commitment to the responsible sourcing of energy and environmental stewardship, STWA combines scientific research with inventive problem solving to provide energy efficiency ‘clean tech’ solutions to bring new efficiencies and lower operational costs to the upstream, midstream and gathering sectors. STWA’s flagship product, AOT (Applied Oil Technology) improves the economics of transporting crude oil by reducing the viscosity of oil in pipelines. Once deployed on pipeline pumping stations, production and transportation companies benefit from the safer, more cost-effective delivery of greater volumes of oil while reducing energy consumption at pumping stations and lowering CO2 emissions.
The AOT technology is the result of years of research conducted at Temple University (Philadelphia, Penn.) and is the world’s first ASME-certified industrial hardware to use the principles of electrorheology, the study of applying non-uniform electrical fields to change the mechanical behavior of fluids, to significantly reduce the viscosity of crude oil within pipelines during maximum flow conditions. Field tested by the U.S. Department of Energy, independent testing laboratories such as ATS RheoSystems and fabricated to exacting industry standards by STWA’s supply chain partners, the efficacy of AOT to increase flow rates, prevent bottlenecks, reduce pump station power consumption, enhance pipeline integrity and optimize flow assurance has been proven repeatedly in the lab and on a 300,000 barrel per day pipeline.
STWA is also commercializing STWA Joule Heat, an energy-efficient technology for heating crude oil in pipelines to improve flow. Unlike traditional trace heating systems which generate heat via a resistive trace heating element which transfers energy into the oil, the STWA solution applies an electrical field directly to oil, generating heat within the flow itself. The result is optimal heat conductivity and performance with less power and in a smaller form factor.
Guided by a dynamic management team led by Greggory Bigger, Chief Executive Officer, Chairman and a strong independent board of directors of energy industry veterans, STWA is a revenue generating company with a solid cash position, clean balance sheet and a proven ability to develop and deliver industrial-grade equipment that support the company’s mission and enhance shareholder value. As the exclusive licensee of oil viscosity reduction processes developed at Temple University and owner of 48 worldwide patents related to the use of electricity to change the mechanical behavior of oil and liquid natural gas, STWA is well-positioned to capitalize on the explosive growth opportunities in the global crude oil production and transportation sector. More information is available at: www.stwa.com. Disclaimer
Save The World Air, Inc. Company Blog
Save The World Air, Inc. News:
STWA Deploys AOT(TM) Viscosity Reduction System on Condensate Pipeline in Eagle Ford
STWA (ZERO) Key Management Featured in Exclusive QualityStocks Interview
STWA (OTCQX: ZERO) Announces Engagement of QualityStocks Investor Relations Services
Zenosense, Inc. (ZENO)
The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO). Today, Zenosense, Inc. closed trading at $0.1689, up 5.43%, on 13,950 volume with 5 trades. The stock’s average daily volume over the past 60 days is 34,912, and its 52-week low/high is $0.15/$1.00.
Zenosense, Inc. (ZENO) is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.
Early detection of MRSA and HAIs in general is vital. Recent studies suggest that implementing prevention practices can lead to up to a 70 percent reduction in certain HAIs with a financial benefit of using these prevention practices estimated to be as high as $25.0 billion to $31.5 billion in medical cost savings in the United States alone (according to a report by the Centers for Disease Control and Prevention, part of the US Department of Health and Human Sciences). Currently, no cost effective early detection device is available.
The Zenosense MRSA detection device is expected to act like a “smoke detector” for MRSA; designed to detect MRSA in the environment or infected patient, even before a patient demonstrates any obvious symptoms, satisfying this huge unmet need.
Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through their subsidiary Zenon Biosystem. The estimated manufacturing cost per device is under $100 USD and possibly as low as $50 USD. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors". The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.
Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors. Both of these teams will fuse together through a high level advisory board of experienced professionals. A cost-effective Zenosense MRSA detection device, once developed, is expected to be in high demand, driven by patient safety, cost and insurance considerations. Disclaimer
Zenosense, Inc. Company Blog
Zenosense, Inc. News:
Zenosense, Inc. - Hospital Collaboration - 400 Person Lung Cancer Detection Trial
Zenosense, Inc.; Stock Now DTC DWAC/FAST Eligible
Zenosense, Inc. Reports Manufacturing of Pre-Commercial Lung Cancer Detection Device
IFAN Financial, Inc. (IFAN)
The QualityStocks Daily Newsletter would like to spotlight IFAN Financial, Inc. (IFAN). Today, IFAN Financial, Inc. closed trading at $0.375, up 1.35%, on 196,512 volume with 72 trades. The stock’s average daily volume over the past 60 days is 646,319, and its 52-week low/high is $0.0114/$1.01.
IFAN Financial, Inc. (IFAN) and its wholly owned subsidiaries, iPIN Technologies and Mobicash America, are engaged in the design, development and distribution of software that enhances and enables mobile payments. The San Diego-based company has a growing portfolio of solutions, including the ability to use a debit card and corresponding PIN number while purchasing online via mobile phone, tablet, or computer and peer-to-peer cash transfers.
Keeping pace with the evolution of the information and communication (ICT) market, iPIN Technologies intends to provide a range of processing services for the industry’s future devices. The company is currently developing a new method of online selling through debit card payments and processing. iPIN technology attaches to any smartphone through the headphone jack and converts the device into a consumer PIN debit, same-as-cash payment solution. Using the iPIN Debit app, transactions are processed through the private and secure iPIN Technologies Network.
Mobicash America is an early-stage technology company that develops mobile payment solutions. The company’s platform product, Quidme, utilizes the text messaging function of a mobile phone, allowing the technology to operate on almost any phone or network, with or without data service. The functionality of the Quidme platform allows users to pay bills, purchase goods and services, and to send money to friends and relatives located locally or internationally via simple text message.
IFAN Financial continues to explore opportunities to expand its product portfolio to meet the growing demands for consumer/merchant convenience, speed and security within the mobile commerce market. Products in development will combine the functionality of social media, e-commerce and banking with the broader conveniences of the mobile environment. Disclaimer
IFAN Financial, Inc. Company Blog
IFAN Financial, Inc. News:
IFAN Financial Reaches Technology Development Milestones
IFAN Financial, Inc. Announces Stock-Based Compensation Plan
IFAN Financial, Inc. Announces the Launch of New Website and Investor Relations Kit
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $7.00, even for the day, on 100 volume with 1 trads. The stock’s average daily volume over the past 60 days is 628, and its 52-week low/high is $3.16/$15.00.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
AV-101, VistaGen's lead small molecule prodrug candidate, has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder
Dr. Gerard Sanacora Joins VistaGen's Clinical and Scientific Advisory Board
VistaGen Signs Letter of Intent With National Institute of Mental Health for NIH-Sponsored Phase 2 Clinical Study of AV-101 in Major Depressive Disorder
Today's Top 3
Wall Street Resources
Fortune Stock Alerts
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Boreal Water Collection, Inc. (BRWC) Releases Open Letter to Shareholders
- Cleartronic, Inc. (CLRI) Announces Expanded License Agreement With Collabria LLC
- Coastal Integrated Services, Inc. (COLV) Announces Subsidiary's Nomination for Prestigious Award
- Consorteum Holdings, Inc. (CSRH) Signs License Agreement With NYG Holdings
- Dominovas Energy Corp. (DNRG) Key Management Featured in Exclusive QualityStocks Interview
- eCareer Holdings, Inc. (ECHI) Reports 1000% Increase in Openreq.com Site Traffic, Seeks to Expand Salesforce
- Falcon Crest Energy (FCEN) Acquires Remaining Working Interest in Rocky Ford Field
- IFAN Financial, Inc. (IFAN) Reaches Technology Development Milestones
- International Stem Cell Corp. (ISCO) Announces Completion of Cell Bank for Parkinson's Disease Clinical Trial
- MIT Holding, Inc. (MITD) Launches New Website with Investor Relations Suite
- Mobile Lads Corp. (MOBO) Purchases Majority of North American Shopping Network From Domark International
- One World Holdings, Inc. (OWOO) The One World Doll Project CEO Announces 2015 Revenue Projections in Stockholder Letter
- Pure Hospitality Solutions, Inc. (PNOW) anticipates $40 Million Oveedia Valuation with Divest and Focus Strategy
- Resort Savers, Inc. (RSSV) Closes $2M Investment
- Save The World Air, Inc. (ZERO) Deploys AOT(TM) Viscosity Reduction System on Condensate Pipeline in Eagle Ford
- Sibling Group Holdings, Inc. (SIBE) Urban Planet Mobile Announces Partnership for Writing Planet in Hong Kong Secondary Schools
- Sparta Commercial Services, Inc. (SRCO) Reports Continued Sales Growth
- Start Scientific, Inc. (STSC) Signs Farmout Agreement With Durban Energy
- VistaGen Therapeutics, Inc. (VSTA) and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder
- Well Power Inc. (WPWR) to host second webinar on proprietory micro-refinery technology
- Zenosense, Inc. (ZENO) Hospital Collaboration - 400 Person Lung Cancer Detection Trial